Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16229388 | 0.89 | SIRT1 (0.81) | SIRT1SIRT2ALDH1A1KMT2AMAPT | |
| SCHEMBL14095988 | 0.88 | SIRT1 (0.64) | SIRT1ALDH1A1LMNAMAPK1SMPD1 | |
| SCHEMBL4368732 | 0.87 | SIRT1 (0.56) | SIRT1SIRT2ALDH1A1LMNAMAPK1 | |
| SCHEMBL4363717 | 0.86 | SIRT1 (0.55) | SIRT1SIRT2ALDH1A1LMNAMAPK1 | |
| SCHEMBL4369732 | 0.82 | SIRT2 (0.64) | SIRT1SIRT2ALDH1A1LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL1707264 | 0.82 | SIRT1 (0.66) | SIRT1ALDH1A1LMNAMAPK1ROCK2 | |
| Hydrochloric Acid SCHEMBL1707261 | 0.82 | SIRT1 (0.66) | SIRT1ALDH1A1LMNAMAPK1ROCK2 | |
| SCHEMBL4363690 | 0.80 | ALDH1A1 (0.63) | SIRT1SIRT2ALDH1A1LMNAKMT2A | |
| SCHEMBL17826591 | 0.80 | SIRT1 (0.80) | SIRT1SIRT2 | |
| SCHEMBL4362115 | 0.79 | SIRT2 (0.60) | SIRT1SIRT2ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | SIRT1 4376/4885SIRT2 4612/4885ALDH1A1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.